Skip to main navigation
Skip to search
Skip to main content
Sort by
Keyphrases
Breast Cancer Patients
100%
Human Epidermal Growth Factor Receptor 2 (HER2)
100%
Her2neu
100%
Overexpressing
28%
Cancer Cells
28%
Emodin
21%
Tumor Cells
14%
In Cancer
14%
Survival Rate
14%
Promoter Activity
14%
Transcriptional Regulator
14%
HER2/neu Overexpression
14%
Gene Expression
7%
Tyrosine Kinase Activity
7%
Tumor
7%
Ovarian Cancer
7%
Breast Cancer
7%
Tumor Suppressor Gene
7%
Apoptosis
7%
Malignancy
7%
Overexpression
7%
Patients with Cancer
7%
Tyrosine Kinase Inhibitor
7%
Phase I Study
7%
Doxorubicin
7%
Phase I Trial
7%
Paclitaxel
7%
Cisplatin
7%
Cancer Treatment
7%
Breast
7%
HER2 Receptor
7%
Anti-HER2
7%
Metastatic Breast Cancer
7%
Transcriptional Repressor
7%
Clinical Trials
7%
Unfavorable Prognosis
7%
Family Members
7%
Repressor
7%
Breast Cancer Cells
7%
Cancer Therapy
7%
Etoposide
7%
Tumor-free Survival
7%
Human Cancer
7%
Liposomes
7%
Ascites
7%
Therapeutic Efficacy
7%
Gene Therapy
7%
Adenovirus Type 5
7%
Genentech
7%
Molecular Events
7%
C-erbB-2
7%
Transformed Phenotype
7%
Neu Oncogene
7%
Multiple Persons
7%
Pleural Effusion
7%
Oncogenic Activity
7%
PEA3
7%
Relapse Time
7%
Clinical Potential
7%
San Francisco
7%
Non-cancer Cell
7%
HER2/neu Expression
7%
Trastuzumab/Herceptin
7%
Tumor Suppression Mechanism
7%
Pharmacology, Toxicology and Pharmaceutical Science
Malignant Neoplasm
100%
Breast Cancer
100%
Neoplasm
42%
Emodin
42%
Clinical Trial
28%
Survival Rate
28%
Trastuzumab
28%
Protein Tyrosine Kinase
14%
Tumor Suppressor Protein
14%
Protein Tyrosine Kinase Inhibitor
14%
Doxorubicin
14%
Cisplatin
14%
Paclitaxel
14%
Epidermal Growth Factor Receptor 2
14%
Ovary Cancer
14%
Metastatic Breast Cancer
14%
Etoposide
14%
Liposome
14%
Ascites
14%
Preclinical Study
14%
Cancer Inhibition
14%
Pleura Effusion
14%
Human Adenovirus 5
14%
Oncogenic activity
14%
Immunology and Microbiology
HER2/neu
100%
Cancer Cell
22%
Emodin
16%
Promoter Region
11%
Tumor Cell
11%
Tyrosine
11%
Repressor Gene
11%
Downregulation
11%
Survival Rate
11%
Trastuzumab
11%
Phosphotransferase
11%
Kinase
11%
Tumor Suppressor Gene
5%
Programmed Cell Death
5%
Gene Expression
5%
Human Adenovirus 5
5%
Preclinical Study
5%
Oncogene Neu
5%
In Vitro
5%
Biochemistry, Genetics and Molecular Biology
HER2/neu
100%
Cancer Cell
22%
Clinical Trial
11%
Promoter Region
11%
Downregulation
11%
Survival Rate
11%
Trastuzumab
11%
Gene Expression
5%
Tumor Suppressor Gene
5%
Programmed Cell Death
5%
Tyrosine Kinase Inhibitor
5%
Receptor Tyrosine Kinase
5%
Tyrosine Kinase
5%
Doxorubicin
5%
Cisplatin
5%
Transcriptional Repressor
5%
Repressor
5%
Gene Therapy
5%
In Vivo Study
5%
Oncogene Neu
5%
Human Adenovirus 5
5%
Preclinical Study
5%
Oncogenic activity
5%